Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD

23.09  +0.46 (+2.03%)

Premarket: 23.06 -0.03 (-0.13%)

Fundamental Rating

6

Overall GMAB gets a fundamental rating of 6 out of 10. We evaluated GMAB against 559 industry peers in the Biotechnology industry. GMAB scores excellent on profitability, but there are some minor concerns on its financial health. GMAB has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

GMAB had positive earnings in the past year.
In the past year GMAB has reported a negative cash flow from operations.
In the past 5 years GMAB has always been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

Looking at the Return On Assets, with a value of 36.16%, GMAB belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
GMAB has a Return On Equity of 44.97%. This is amongst the best in the industry. GMAB outperforms 98.39% of its industry peers.
The Return On Invested Capital of GMAB (37.15%) is better than 99.46% of its industry peers.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 14.78%.
The last Return On Invested Capital (37.15%) for GMAB is above the 3 year average (15.19%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROIC 37.15%
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

Looking at the Profit Margin, with a value of 29.99%, GMAB belongs to the top of the industry, outperforming 96.96% of the companies in the same industry.
GMAB's Profit Margin has declined in the last couple of years.
GMAB has a better Operating Margin (33.50%) than 98.03% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
GMAB has a Gross Margin of 95.91%. This is amongst the best in the industry. GMAB outperforms 95.35% of its industry peers.
GMAB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so GMAB is creating value.
GMAB has less shares outstanding than it did 1 year ago.
The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
Compared to 1 year ago, GMAB has a worse debt to assets ratio.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

GMAB has an Altman-Z score of 46.45. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GMAB (46.45) is better than 98.21% of its industry peers.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 46.45
ROIC/WACC5.24
WACC7.09%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 5.34 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Current ratio of 5.34. This is comparable to the rest of the industry: GMAB outperforms 55.64% of its industry peers.
GMAB has a Quick Ratio of 5.32. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GMAB (5.32) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 5.32
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.30% over the past year.
The Earnings Per Share has been growing by 29.12% on average over the past years. This is a very strong growth
The Revenue for GMAB has decreased by -55.29% in the past year. This is quite bad
The Revenue has been decreasing by -9.38% on average over the past years.
EPS 1Y (TTM)48.3%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%7.11%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%22.3%

3.2 Future

Based on estimates for the next years, GMAB will show a small growth in Earnings Per Share. The EPS will grow by 6.87% on average per year.
GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.13% yearly.
EPS Next Y-12.51%
EPS Next 2Y2.37%
EPS Next 3Y8.76%
EPS Next 5Y6.87%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y12.13%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.66, the valuation of GMAB can be described as very reasonable.
Based on the Price/Earnings ratio, GMAB is valued cheaper than 96.60% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, GMAB is valued rather cheaply.
With a Price/Forward Earnings ratio of 11.25, the valuation of GMAB can be described as very reasonable.
95.89% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.39.
Industry RankSector Rank
PE 11.66
Fwd PE 11.25
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 93.38% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 31.87
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.4
EPS Next 2Y2.37%
EPS Next 3Y8.76%

More info and screens

0

5. Dividend

5.1 Amount

GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENMAB A/S -SP ADR

NASDAQ:GMAB (6/12/2025, 8:00:01 PM)

Premarket: 23.06 -0.03 (-0.13%)

23.09

+0.46 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners40.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.22B
Analysts77.24
Price Target120.41 (421.48%)
Short Float %0.46%
Short Ratio1.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)94.94%
Min EPS beat(2)60.73%
Max EPS beat(2)129.15%
EPS beat(4)3
Avg EPS beat(4)45.51%
Min EPS beat(4)-11.29%
Max EPS beat(4)129.15%
EPS beat(8)6
Avg EPS beat(8)31.05%
EPS beat(12)8
Avg EPS beat(12)29.15%
EPS beat(16)11
Avg EPS beat(16)28.87%
Revenue beat(2)0
Avg Revenue beat(2)-1.17%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-4.27%
Max Revenue beat(4)4.57%
Revenue beat(8)5
Avg Revenue beat(8)1.06%
Revenue beat(12)9
Avg Revenue beat(12)2.95%
Revenue beat(16)13
Avg Revenue beat(16)3.63%
PT rev (1m)0%
PT rev (3m)-23.03%
EPS NQ rev (1m)5.48%
EPS NQ rev (3m)34.54%
EPS NY rev (1m)0.7%
EPS NY rev (3m)6.76%
Revenue NQ rev (1m)-3.64%
Revenue NQ rev (3m)-1.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 11.66
Fwd PE 11.25
P/S 11.52
P/FCF N/A
P/OCF N/A
P/B 17.28
P/tB 28.73
EV/EBITDA 31.87
EPS(TTM)1.98
EY8.58%
EPS(NY)2.05
Fwd EY8.89%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2
BVpS1.34
TBVpS0.8
PEG (NY)N/A
PEG (5Y)0.4
Profitability
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROCE 45.64%
ROIC 37.15%
ROICexc 83.17%
ROICexgc 439.3%
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
FCFM N/A
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score6
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.05
Cap/Depr 76.79%
Cap/Sales 0.61%
Interest Coverage 8004.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 5.32
Altman-Z 46.45
F-Score6
WACC7.09%
ROIC/WACC5.24
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)48.3%
EPS 3Y38.63%
EPS 5Y29.12%
EPS Q2Q%7.11%
EPS Next Y-12.51%
EPS Next 2Y2.37%
EPS Next 3Y8.76%
EPS Next 5Y6.87%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%22.3%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y12.13%
EBIT growth 1Y-53.2%
EBIT growth 3Y-28.52%
EBIT growth 5Y-16.38%
EBIT Next Year31.35%
EBIT Next 3Y25.55%
EBIT Next 5Y13.92%
FCF growth 1Y-101.46%
FCF growth 3Y-16.81%
FCF growth 5Y-1.31%
OCF growth 1Y-100.64%
OCF growth 3Y-19%
OCF growth 5Y-2.24%